Speaker illustration

Professor John Kastelein

Faculty of Medecine - University of Amsterdam, Amsterdam (Netherlands (The))

Member of:

European Society of Cardiology

Short biography of John J.P. Kastelein, MD PhD FESC Dr. Kastelein (1954) is Emeritus Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he held the Strategic Chair of Genetics of Cardiovascular Disease. Professor Kastelein has published over 890 research papers in peer reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA and Circulation and has a Hirsch index of 130 in February 2019. His citations reached over 7000 in 2020 and in total over 80.000 Source: Web of Science John J.P. Kastelein is currently an operating partner at Forbion Capital Management, Naarden, the Netherlands, with a specialized focus on cardiometabolic disease. He is CSO of NewAmsterdam Pharma and acting chief medical officer (CMO) of Statin Biotechnology Inc., a company developing a monoclonal antibody (Mab) against apolipoprotein CIII .

A decade of innovation, guidelines and paradigm shifts in LDL-C management (10th annual symposium)

Event: ESC Congress 2022

Topic: Lipid-Lowering Agents

Session type: Satellite Symposium

Thumbnail

LDL lowering – dealing with difficult situations

Event: ESC Congress 2021 - The Digital Experience

Topic: Pharmacology and Pharmacotherapy

Session type: Cardiology Toolbox

Thumbnail

Redefining intensive LDL-c management in high risk patients: The case for combination therapy

Event: ESC Congress 2021 - The Digital Experience

Topic: Risk Factors and Prevention

Session type: Satellite Symposium

Thumbnail

Lower for Longer: Reducing Cumulative Exposure to Elevated LDL-C to Prevent Cardiovascular Disease

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Treatment

Session type: Industry Live

Thumbnail

PCSK9i & LDL-c: Guidelines, Practice & Innovation: Review of facts and opportunities

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Treatment

Session type: Industry Q&A session

Thumbnail

LDL-c guidance on the novel ESC/EAS dyslipidaemia guidelines: expert discussions on practical implications

Event: ESC CONGRESS 2019

Topic: Risk Factors and Prevention

Session type: Satellite Symposium

Thumbnail

Insights and innovation - Can we alter the course of atherosclerotic cardiovascular disease?

Event: ESC CONGRESS 2019

Topic: Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)

Session type: Satellite Symposium

Thumbnail

Beyond statins - Evolving concepts for the management of dyslipidaemia

Event: ESC CONGRESS 2019

Topic: Risk Factors and Prevention

Session type: Satellite Symposium

Thumbnail

PCSK9i, changing practice in cardiology: the emerging story

Event: ESC CONGRESS 2019

Topic: Risk Factors and Prevention

Session type: Satellite Symposium

Thumbnail

PCSK9 inhibition: science, outcomes and guidance (EBAC Accredited)

Event: ESC Congress 2018

Topic: Risk Factors and Prevention

Session type: Satellite Symposium

Thumbnail

This platform is supported by

logo Novo Nordisk